Carolina Liquid Chemistries Promotes Family of Clinical Chemistry Analyzers
|
By LabMedica International staff writers Posted on 31 Jul 2018 |

Image: The EasyRA high-speed benchtop analyzer (Photo courtesy of Carolina Liquid Chemistries).
Carolina Liquid Chemistries (Greensboro, NC, USA) promoted its EasyRA high-speed benchtop analyzer, its family of clinical chemistry analyzers, CLC800, CLC1600, CLC6410, and extensive menu of reagents at the 70th annual AACC Scientific Meeting & Clinical Lab Expo held from July 31 – August 2. The company also introduced the Maglumi 2000 immunoassay analyzer at the event held in Chicago, USA.
Carolina Liquid Chemistries offers an extensive clinical chemistry reagent menu, ranging from general chemistries to urine drug screens and cardiovascular tests such as LpPLA2. The company markets a complete line of cost effective chemistry analyzers and service options for clinical laboratories of all sizes.
At AACC 2018, Carolina Liquid Chemistries highlighted the EasyRA, a high-speed benchtop clinical chemistry analyzer that accommodates the diverse needs of small to medium sized laboratories. Its all-in-one system allows laboratories to perform moderately complex urine drug screens and general chemistry tests on a single analyzer. With 300 tests per hour (480 with integrated ISE), an intuitive user interface, and the ability to analyze STAT samples in less than eight minutes, it is well suited for a variety of clinical laboratories located in satellite facilities, physician offices, pain management clinics, and urgent care centers.
In addition to the EasyRA, the company highlighted its family of floor model chemistry analyzers, the CLC800, CLC1600, and the CLC6410, which offer high throughputs from 400 to 900 to 3,200 photometric tests per hour. The FDA-cleared clinical chemistry analyzers are excellent for clinical laboratories located in mid-size group practices, large clinics, small and large hospitals or reference laboratories of all sizes.
Carolina Liquid Chemistries also highlighted its extensive reagent menu of products for both general chemistry and urine drug testing. This included 40 general chemistries, 27 urine drug screens, 15 immunochemistries and 24 special chemistries, including vLp-PLA2 (PLAC), Vitamin D (2-part), Procalcitonin (PCT) and Human Κ/λ Free Light Chain. Also on display at the event was the Maglumi 2000 immunoassay analyzer.
Carolina Liquid Chemistries offers an extensive clinical chemistry reagent menu, ranging from general chemistries to urine drug screens and cardiovascular tests such as LpPLA2. The company markets a complete line of cost effective chemistry analyzers and service options for clinical laboratories of all sizes.
At AACC 2018, Carolina Liquid Chemistries highlighted the EasyRA, a high-speed benchtop clinical chemistry analyzer that accommodates the diverse needs of small to medium sized laboratories. Its all-in-one system allows laboratories to perform moderately complex urine drug screens and general chemistry tests on a single analyzer. With 300 tests per hour (480 with integrated ISE), an intuitive user interface, and the ability to analyze STAT samples in less than eight minutes, it is well suited for a variety of clinical laboratories located in satellite facilities, physician offices, pain management clinics, and urgent care centers.
In addition to the EasyRA, the company highlighted its family of floor model chemistry analyzers, the CLC800, CLC1600, and the CLC6410, which offer high throughputs from 400 to 900 to 3,200 photometric tests per hour. The FDA-cleared clinical chemistry analyzers are excellent for clinical laboratories located in mid-size group practices, large clinics, small and large hospitals or reference laboratories of all sizes.
Carolina Liquid Chemistries also highlighted its extensive reagent menu of products for both general chemistry and urine drug testing. This included 40 general chemistries, 27 urine drug screens, 15 immunochemistries and 24 special chemistries, including vLp-PLA2 (PLAC), Vitamin D (2-part), Procalcitonin (PCT) and Human Κ/λ Free Light Chain. Also on display at the event was the Maglumi 2000 immunoassay analyzer.
Latest AACC 2018 News
- Mesa Biotech Showcases PCR Testing Platform at Clinical Expo
- Mindray Medical Unveils Chemiluminescence Immunoassay System at AACC 2018
- Abbott Diagnostics Displays Alinity Family of Systems
- Roche Diagnostics Highlights Latest Clinical Lab Solutions at AACC
- Sysmex Highlights Innovations in Flow Cytometry, Urinalysis and Hematology
- Ortho Clinical Diagnostics Unveils Next-Gen Analyzer at Lab Show
- Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers
- Thermo Fisher Scientific Showcases Product Portfolio at Lab Trade Show
- EKF Diagnostics Highlights Assay Kit and POC Analyzer at AACC 2018
- Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo
- Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio
- Beckman Coulter Features New Hematology Analyzers and Lab Automation
- Orion Diagnostica Showcases Rapid Test and Molecular Platform at Lab Show
- Saladax Biomedical Launches Game-Changing Assays at AACC 2018
- SeraCare Life Sciences Promotes New AccuSpan Panel at Lab Expo
- Sekisui Diagnostics Showcases Clinical Chemistry and Immunoassay Analyzers
Channels
Clinical Chemistry
view channel
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read more
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
AI Tool Improves Accuracy of Cancer Liquid Biopsy for Therapy Selection
Liquid biopsy is increasingly used to guide targeted therapy by detecting tumor-derived mutations in blood, but distinguishing true tumor signals from background noise remains challenging.... Read more
Study Highlights Inherited Breast Cancer Risk Genes in Young Black Women
Early-onset breast cancer remains a significant concern, with some cases presenting as triple-negative disease, one of its most aggressive forms. Black women face disproportionately elevated risks of developing... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more









